Andrographis Anti-Inflammatory Effects

Andrographolide is one of the most potent natural-product inhibitors of NF-kB (nuclear factor kappa-B) signaling identified to date. The mechanism is unusually elegant: the alpha,beta-unsaturated lactone functional group of andrographolide forms a covalent bond with cysteine 62 of the NF-kB p50 subunit (demonstrated definitively by Xia and colleagues in 2004), blocking the p50/p65 heterodimer from binding kappa-B promoter elements in DNA. The downstream consequence is sweeping suppression of NF-kB-driven gene expression: TNF-alpha, IL-1-beta, IL-6, COX-2, iNOS, ICAM-1, VCAM-1, E-selectin, and dozens of other inflammatory mediators are downregulated simultaneously. This single-target/multi-effect profile is why a single botanical can produce measurable benefit across rheumatoid arthritis (Burgos 2009 trial), osteoarthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease, and acute lung injury models — all of which are downstream of NF-kB-driven cytokine cascades. This deep-dive walks through the molecular mechanism, the clinical trial evidence in each indication, the JBP485-related drug transporter interaction relevant to pharmacokinetics, and the practical considerations for clinical use.

Table of Contents

1. NF-kB as the Master Regulator of Inflammation
2. Cysteine-62 Covalent Inhibition (Xia 2004)
3. Downstream Cytokine Suppression (TNF, IL-1, IL-6)
4. COX-2 and iNOS Downregulation
5. ICAM-1 / VCAM-1 Endothelial Adhesion Suppression
6. Rheumatoid Arthritis: The Burgos 2009 Trial
7. Osteoarthritis
8. Ankylosing Spondylitis and Psoriasis
9. Acute Lung Injury and Cytokine Storm Models
10. JBP485 / PEPT1 Transporter Pharmacokinetic Interaction
11. Comparison with NSAIDs and Biologic Anti-TNF Therapy
12. Cautions and Drug Interactions
13. Key Research Papers
14. Connections

NF-kB as the Master Regulator of Inflammation

NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) is the transcription factor system that orchestrates the cellular response to inflammatory and stress signals across essentially all cell types in the body. Activation of NF-kB downstream of TNF-alpha, IL-1, TLR agonists (LPS, viral RNA, bacterial DNA), reactive oxygen species, or DNA damage produces a coordinated transcriptional response — upregulation of inflammatory cytokines (TNF-alpha, IL-1-beta, IL-6, IL-8), prostaglandin/leukotriene synthesizing enzymes (COX-2, iNOS), endothelial adhesion molecules (ICAM-1, VCAM-1, E-selectin), antiapoptotic proteins (Bcl-xL, c-FLIP, cIAP1/2), and matrix metalloproteinases (MMP-1, MMP-3, MMP-9).

The architecture: NF-kB is a family of dimeric transcription factors built from five subunits (p50, p52, p65/RelA, RelB, c-Rel). The most common active form is the p50/p65 heterodimer. In resting cells, the dimer is held in the cytoplasm bound to the inhibitor protein I-kB-alpha. Upon activation, the upstream IkB kinase (IKK) complex phosphorylates I-kB-alpha, targeting it for ubiquitination and proteasomal degradation, which releases the p50/p65 heterodimer to translocate to the nucleus where it binds kappa-B promoter elements and activates transcription.

The therapeutic problem with NF-kB as a target: it is essential for normal immune defense, normal lymphoid development, and normal cellular stress response. Complete blockade is incompatible with life. The successful pharmaceutical anti-inflammatory strategy has therefore been to target downstream effectors (anti-TNF biologics, anti-IL-1 biologics, anti-IL-6 biologics, JAK inhibitors) rather than NF-kB itself.

Andrographolide is unusual in producing partial, selective NF-kB inhibition that reduces the inflammatory transcriptional program without abolishing it. The cysteine-62 mechanism is selective enough to spare some NF-kB functions while clearly attenuating others, producing measurable clinical benefit in autoimmune indications with tolerability that is closer to NSAIDs than to biologics or corticosteroids.

Back to Table of Contents

Cysteine-62 Covalent Inhibition (Xia 2004)

The molecular basis for andrographolide's NF-kB inhibition was definitively established by Xia and colleagues (Wuhan University) in a 2004 Journal of Immunology paper. Using a combination of computational docking, site-directed mutagenesis, mass spectrometry, and gel-shift assays, they demonstrated:

1. Andrographolide forms a covalent adduct specifically with the cysteine-62 residue of the NF-kB p50 subunit, via Michael addition of the cysteine thiol to the alpha,beta-unsaturated lactone of andrographolide
2. Mutation of p50 Cys-62 to alanine eliminates the inhibitory effect of andrographolide on NF-kB DNA binding
3. The covalent modification blocks the p50/p65 heterodimer from binding kappa-B promoter elements in DNA, preventing transcription of downstream target genes
4. The effect is selective for NF-kB — andrographolide does not similarly modify cysteines on other transcription factors (NFAT, AP-1, STAT3) at comparable concentrations
5. The effect occurs at micromolar concentrations clinically achievable with oral dosing of standardized Andrographis extracts

The cysteine-62 mechanism places andrographolide in a small class of natural-product covalent NF-kB inhibitors that includes parthenolide (from feverfew), helenalin (from arnica), and several sesquiterpene lactones from the daisy family. The "Michael acceptor" alpha,beta-unsaturated carbonyl functional group is the common chemical handle that allows these molecules to covalently modify cysteine thiols on regulatory proteins.

A practical consequence: because the inhibition is covalent, the duration of effect outlasts the plasma half-life of andrographolide itself. New synthesis of unmodified p50 subunit is required to restore full NF-kB activity, which takes hours rather than the minutes that would be characteristic of a non-covalent reversible inhibitor. This is part of why a thrice-daily dosing schedule (rather than continuous IV infusion) is clinically sufficient.

Back to Table of Contents

Downstream Cytokine Suppression (TNF, IL-1, IL-6)

The single most clinically impactful consequence of NF-kB inhibition is reduced transcription of the inflammatory cytokine triumvirate that drives most chronic inflammatory disease:

• TNF-alpha — the master inflammatory cytokine, central to rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, ankylosing spondylitis. The targets of infliximab, adalimumab, etanercept, golimumab, certolizumab.
• IL-1-beta — the cytokine of acute inflammation, central to gout, autoinflammatory syndromes (familial Mediterranean fever, cryopyrin-associated periodic syndromes), and atherosclerosis. The target of anakinra and canakinumab.
• IL-6 — the cytokine of chronic inflammation and acute-phase response, central to rheumatoid arthritis, giant cell arteritis, Castleman's disease, and cytokine release syndrome from CAR-T therapy. The target of tocilizumab and sarilumab.

Andrographolide simultaneously reduces transcription of all three cytokines through the upstream NF-kB inhibition. In cell-culture studies of LPS-stimulated macrophages, andrographolide at 5-30 micromolar concentrations reduces TNF-alpha production by 50-80%, IL-1-beta production by 40-70%, and IL-6 production by 40-70%. The effect is dose-dependent and reproducible across multiple macrophage cell lines and primary macrophage cultures.

In animal models of acute inflammation (LPS-induced endotoxemia, collagen-induced arthritis, dextran-sulfate-induced colitis), oral andrographolide administration produces measurable reduction in serum cytokine levels and corresponding reduction in clinical disease severity scores. The effect is generally smaller than that of biologic anti-cytokine therapy but is achieved with an oral small-molecule botanical at a tiny fraction of the cost.

Back to Table of Contents

COX-2 and iNOS Downregulation

Beyond cytokines, NF-kB activation drives transcription of two other inflammation-amplifying enzymes:

• COX-2 (cyclooxygenase-2) — the inducible isoform of cyclooxygenase that generates prostaglandin E2 and prostaglandin I2 from arachidonic acid at sites of inflammation. The principal target of NSAIDs and the more selective coxib drugs (celecoxib, etoricoxib).
• iNOS (inducible nitric oxide synthase, NOS2) — generates large quantities of nitric oxide from arginine in activated macrophages and other inflammatory cells. The high-output nitric oxide reacts with superoxide to form peroxynitrite, a major mediator of inflammatory tissue damage and oxidative stress.

Andrographolide downregulates both COX-2 and iNOS transcription via NF-kB inhibition. The COX-2 effect produces a mild prostaglandin-reducing anti-inflammatory effect comparable to (but smaller than) ibuprofen or naproxen, with the advantage of being achieved without the COX-1 inhibition that drives the gastrointestinal toxicity of NSAIDs. The iNOS effect reduces inflammatory nitric oxide production without affecting the constitutive endothelial NOS (eNOS) that maintains normal vasodilator tone and blood pressure regulation.

The result is a botanical with a mechanism of action that overlaps with NSAIDs (via COX-2 downregulation) and with the experimental iNOS inhibitor drug class (which has so far failed to produce a viable pharmaceutical), but without the GI bleeding risk of NSAIDs and without the cardiovascular hypertension risk of pharmaceutical iNOS inhibition.

Back to Table of Contents

ICAM-1 / VCAM-1 Endothelial Adhesion Suppression

Leukocyte recruitment from circulation into inflamed tissue requires a coordinated sequence of capture, rolling, firm adhesion, and transmigration across the endothelium. Each step depends on specific adhesion molecules:

• E-selectin and P-selectin — endothelial proteins that mediate initial capture and rolling of leukocytes
• ICAM-1 (intercellular adhesion molecule-1) — mediates firm adhesion of leukocytes to endothelium via leukocyte LFA-1 and Mac-1 integrins
• VCAM-1 (vascular cell adhesion molecule-1) — preferentially recruits monocytes and lymphocytes via VLA-4 integrin, important in chronic inflammation and atherosclerosis

NF-kB drives transcription of all three. Andrographolide inhibition of NF-kB downregulates ICAM-1, VCAM-1, and E-selectin expression on activated endothelium, with the functional consequence of reduced leukocyte recruitment into inflamed tissue. This is an upstream mechanism for reducing inflammatory cell infiltration, complementary to (and in many ways more proximal than) cytokine suppression.

The endothelial adhesion suppression is relevant to chronic vascular inflammation (atherosclerosis), to inflammatory bowel disease (where the integrin antagonist vedolizumab and the anti-MAdCAM-1 antibodies exploit the same biology pharmaceutically), and to autoimmune disease in general where leukocyte recruitment into target tissue is the rate-limiting step in chronic disease progression.

Back to Table of Contents

Rheumatoid Arthritis: The Burgos 2009 Trial

The pivotal clinical trial for Andrographis in rheumatoid arthritis (RA) is Burgos and colleagues 2009, published in Clinical Rheumatology. The trial enrolled 60 adult patients with active RA on stable background DMARD therapy (methotrexate, sulfasalazine, hydroxychloroquine, or combinations) who had inadequate disease control on their existing regimen. Randomization was 1:1 to andrographolide 30 mg three times daily (90 mg/day total) versus matching placebo for 14 weeks.

Primary outcomes:

• Tender joint count (out of 28 joints) reduced significantly more in the andrographolide arm than placebo
• Swollen joint count reduced significantly more in the andrographolide arm than placebo
• Visual analog scale pain score reduced significantly more in the andrographolide arm
• Patient global health assessment improved significantly more in the andrographolide arm
• Composite Disease Activity Score (DAS28) improved more in the andrographolide arm

Secondary outcomes:

• Rheumatoid factor and IgA levels modestly decreased in the andrographolide arm, suggesting reduced B-cell autoantibody production
• C-reactive protein modestly decreased (consistent with reduced IL-6 production from the NF-kB inhibition mechanism)
• Tolerability was excellent — no serious adverse events attributable to andrographolide. The most common AE was the well-known bitter taste at the higher dose.

The effect size was clinically meaningful but modest — smaller than what would be expected from a biologic anti-TNF or anti-IL-6 agent, but achieved as an oral adjunct to existing DMARD therapy with excellent tolerability and a tiny fraction of the cost. Andrographis at 90 mg andrographolide per day is a reasonable adjunct for RA patients with persistent symptoms on conventional DMARDs who are seeking additional symptom control before escalating to biologic therapy, or who cannot afford biologics.

See our Arthritis page for the broader context of RA management.

Back to Table of Contents

Osteoarthritis

Osteoarthritis (OA) is mechanistically distinct from RA — primarily a non-autoimmune disease of cartilage breakdown driven by mechanical wear, age, obesity, and prior joint injury. However, there is now ample evidence that chronic low-grade inflammation in the synovial membrane (synovitis) is a substantial contributor to OA pain and to ongoing cartilage damage. The same NF-kB-driven inflammatory cytokines (TNF-alpha, IL-1-beta, IL-6) are upregulated in OA synovium and contribute to chondrocyte production of cartilage-degrading matrix metalloproteinases.

Several small clinical trials have evaluated Andrographis or andrographolide-enriched extracts in knee and hand OA, generally reporting modest improvement in pain scores and function indices comparable to a low-dose NSAID. Effect sizes are smaller than for the established OA interventions (weight loss, structured exercise, physical therapy, topical or oral NSAIDs, intra-articular hyaluronate or steroid injection), but Andrographis is well-tolerated as an adjunct or as a partial alternative for patients who cannot tolerate NSAIDs due to GI bleeding risk, renal function, or cardiovascular comorbidity.

Reasonable adult OA dosing: standardized extract 300-600 mg twice daily, ongoing as long as benefit is perceived. May be combined with curcumin (turmeric) 500-1,000 mg twice daily and Boswellia serrata extract 300-500 mg twice daily for additive effect via different anti-inflammatory mechanisms (curcumin inhibits NF-kB via a different mechanism, Boswellia inhibits 5-lipoxygenase reducing leukotriene production).

Back to Table of Contents

Ankylosing Spondylitis and Psoriasis

Ankylosing spondylitis (AS) and psoriasis (and their related conditions psoriatic arthritis and other spondyloarthritides) are linked by their dependence on the IL-23 / IL-17 / Th17 axis. The pharmaceutical drug class that targets this axis (IL-17 antagonists secukinumab, ixekizumab; IL-23 antagonists guselkumab, risankizumab, tildrakizumab) has been transformative for these conditions over the past decade.

Andrographolide's NF-kB inhibition reduces IL-6 and TNF-alpha production by activated dendritic cells and Th17 cells, with downstream effects on Th17 differentiation and IL-17 production. The mechanism is mechanistically aligned with the IL-23/IL-17 axis biology even if andrographolide is not directly targeting the cytokines themselves.

Clinical evidence is limited to small open-label trials, case series, and one small randomized trial in AS showing modest reduction in BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) scores. Andrographis is a reasonable adjunct in AS and psoriasis for patients on conventional DMARDs (sulfasalazine, methotrexate) who are seeking additional symptom control short of escalating to biologics, or as part of a comprehensive anti-inflammatory dietary and supplement program.

Back to Table of Contents

Acute Lung Injury and Cytokine Storm Models

Acute lung injury (ALI) and its severe form acute respiratory distress syndrome (ARDS) are driven by overwhelming pulmonary inflammation in response to triggers including sepsis, severe viral pneumonia (influenza, RSV, historical SARS), aspiration, and major trauma. The pathophysiology centers on alveolar macrophage TNF-alpha and IL-6 release driving neutrophil recruitment, capillary leak, surfactant inactivation, and ultimately diffuse alveolar damage.

Multiple animal-model studies document that andrographolide administration substantially attenuates LPS-induced and influenza-induced acute lung injury through the predictable NF-kB-mediated reduction in TNF-alpha, IL-6, and neutrophil recruitment. The Bao 2009 paper in the American Journal of Respiratory and Critical Care Medicine established andrographolide as a candidate molecule for further drug development in airway inflammatory disease, with detailed mechanistic work in ovalbumin-induced asthma models.

It is important to be clear about scope: animal-model evidence does not translate directly to human ARDS management, and Andrographis is not a substitute for the established ARDS interventions (lung-protective ventilation, prone positioning, fluid management, treatment of the underlying trigger). The acute lung injury mechanism is, however, mechanistically illuminating about why Andrographis produces broad reduction in symptom severity in viral URTI — the lung-injury cytokine cascade is a smaller, less severe version of the same biology playing out in uncomplicated influenza and the common cold.

Back to Table of Contents

JBP485 / PEPT1 Transporter Pharmacokinetic Interaction

An interesting but underappreciated pharmacokinetic feature of andrographolide is its interaction with the oligopeptide transporters PEPT1 (intestinal, SLC15A1) and PEPT2 (renal proximal tubule, SLC15A2). These transporters normally absorb small di- and tri-peptides from the gut lumen and reabsorb filtered peptides in the kidney. They also serve as the absorption mechanism for several pharmaceutical drugs designed as peptide mimetics, including the beta-lactam antibiotics (cefadroxil, amoxicillin), the ACE inhibitor enalapril, the antiviral valacyclovir, and the experimental hepatoprotective dipeptide JBP485 (Cyclo-trans-4-L-hydroxyprolyl-L-serine).

Andrographolide interacts with PEPT1 and PEPT2 in a manner that can:

• Modestly compete with substrate drugs for absorption, potentially reducing the bioavailability of co-administered PEPT1-substrate drugs (clinically minor for most patients but worth physician awareness for those on multiple PEPT1-substrate medications)
• Modestly inhibit renal reabsorption of PEPT2-substrate drugs, potentially accelerating their elimination
• Modulate the absorption and disposition of the experimental JBP485, a dipeptide hepatoprotectant that has been studied as an Andrographis adjunct in liver-injury models

For most patients on most medications, the PEPT1/PEPT2 interaction is clinically minor and does not require dose adjustment. The interaction matters most for patients on the antiviral valacyclovir (used for recurrent herpes simplex or zoster prophylaxis), where there is a theoretical risk of modestly reduced valacyclovir absorption when taken concurrently with Andrographis. Separate the two by 2-3 hours if both are required.

Back to Table of Contents

Comparison with NSAIDs and Biologic Anti-TNF Therapy

Where does Andrographis fit in the anti-inflammatory therapeutic landscape?

The honest positioning: Andrographis is an adjunct, not a replacement, for established DMARDs and biologics in moderate-to-severe autoimmune disease. Its niche is in mild disease where conventional DMARDs would be over-treatment, as an adjunct to existing DMARDs for patients with persistent symptoms, as a partial alternative to NSAIDs for patients who cannot tolerate them, and as a long-term anti-inflammatory adjunct in patients seeking to reduce cumulative anti-inflammatory drug burden.

Back to Table of Contents

Cautions and Drug Interactions

• Pregnancy — absolute contraindication. Uterine stimulant. Reiterated on every Andrographis page.
• Anticoagulants and antiplatelets — Andrographis modestly potentiates warfarin, dabigatran, apixaban, rivaroxaban, aspirin, clopidogrel. Monitor for bleeding signs. Discontinue 7 days before elective surgery.
• Immunosuppressants for organ transplant or biologic anti-TNF therapy — complex interactions. Discuss with prescribing physician. Generally avoid in organ transplant; reasonable to combine with low-dose conventional DMARDs (methotrexate, sulfasalazine) but discuss with rheumatologist.
• Pharmaceutical NSAIDs — can be used together. The mechanisms are partially overlapping (both produce COX-2 downregulation, but Andrographis works upstream via NF-kB inhibition while NSAIDs work directly on the COX enzymes). Watch for additive GI side effects.
• Antihypertensives — Andrographis modestly reduces blood pressure. Monitor BP.
• Antidiabetics — Andrographis has mild glucose-lowering activity. Monitor blood glucose.
• PEPT1/PEPT2 substrate drugs (valacyclovir, cefadroxil, enalapril) — modest interaction; separate dosing by 2-3 hours if both are required.
• Bitter taste and GI upset — standard tolerability issues; capsules, food, divided dosing.
• Allergic skin rash — rare but documented. Discontinue if rash appears.
• Headache — uncommon, usually mild and transient.
• Pediatric use in autoimmune disease — safety not well established. Use only with pediatric specialist guidance.

Back to Table of Contents

Key Research Papers

1. Xia YF, Ye BQ, Li YD, et al. (2004). Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. Journal of Immunology. — PubMed
2. Burgos RA, Hancke JL, Bertoglio JC, et al. (2009). Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clinical Rheumatology. — PubMed
3. Bao Z, Guan S, Cheng C, et al. (2009). A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway. American Journal of Respiratory and Critical Care Medicine. — PubMed
4. Wang T, Liu B, Zhang W, et al. (2004). Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. Journal of Pharmacology and Experimental Therapeutics. — PubMed
5. Hidalgo MA, Romero A, Figueroa J, et al. (2005). Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. British Journal of Pharmacology. — PubMed
6. Liu J, Wang ZT, Ji LL (2007). In vivo and in vitro anti-inflammatory activities of neoandrographolide. American Journal of Chinese Medicine. — PubMed
7. Chao WW, Lin BF (2010). Isolation and identification of bioactive compounds in Andrographis paniculata (Chuanxinlian). Chinese Medicine. — PubMed
8. Chandrasekaran CV, Thiyagarajan P, Sundarajan K, et al. (2010). Evaluation of the genotoxic potential and acute oral toxicity of standardized extract of Andrographis paniculata (KalmCold). Food and Chemical Toxicology. — PubMed
9. Tang LIC, Ling APK, Koh RY, et al. (2012). Screening of anti-dengue activity in methanolic extracts of medicinal plants. BMC Complementary and Alternative Medicine. — PubMed
10. Liu W, Guo W, Wu J, et al. (2014). A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochemical Pharmacology. — PubMed
11. Lee KC, Chang HH, Chung YH, Lee TY (2011). Andrographolide acts as an anti-inflammatory agent in LPS-stimulated RAW264.7 macrophages by inhibiting STAT3-mediated suppression of the NF-kappaB pathway. Journal of Ethnopharmacology. — PubMed
12. Akbar S (2011). Andrographis paniculata: a review of pharmacological activities and clinical effects. Alternative Medicine Review. — PubMed

PubMed Topic Searches

• PubMed: Andrographolide NF-kB inhibition
• PubMed: Andrographis arthritis trials
• PubMed: Andrographolide COX-2/iNOS
• PubMed: Andrographolide cytokine suppression
• PubMed: Andrographolide PEPT1 transporter

Back to Table of Contents

Connections

• Andrographis Overview
• Andrographis Benefits Hub
• Andrographis for Cold & Flu
• Andrographis Immune Modulation
• Andrographis Liver Protection
• Turmeric (Curcumin)
• Boswellia
• Ginger
• Willow Bark
• Aspirin
• Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Crohn's Disease
• Psoriasis
• All Herbs

Back to Table of Contents